ArticleCureus2023
Orbital Apex Syndrome Secondary to Herpes Zoster Ophthalmicus: A Case of Irreversible Optic Nerve Damage.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Varicella-Zoster Virus and the Eye: Clinical Spectrum, Management, and Vaccination.Pathogens (Basel, Switzerland) · 2026Review
- Orbital Apex Syndrome Following Herpes Zoster Ophthalmicus: A Case Report and Clinical Approach.Clinical case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes zoster ophthalmicus (HZO) arises because of the reactivation of latent varicella-zoster virus (VZV) infection in the trigeminal nerve ganglion and typically presents with ocular manifestations. However, infrequent neurological complications can also be seen. Rarely occurring, orbital apex syndrome presents itself as a severe complication of HZO, characterized by the involvement of multiple cranial nerves and vascular structures within the orbital apex. A 70-year-old male patient being followed for HZO developed orbital apex syndrome after 14 days of treatment, resulting in ophthalmoplegia, vision loss, and significant morbidity. Clinical diagnosis was confirmed by magnetic resonance imaging of the orbit. The treatment involved a combination of systemic steroid and antiviral therapy, resulting in a favorable resolution of ophthalmoplegia within six months. However, optic-neuropathy-induced vision loss was irreparable. Early recognition, antiviral therapy, and multidisciplinary management are crucial in preventing permanent visual impairment and neurological deficits associated with this uncommon complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.